Syngene International is betting on its first global Phase 3 clinical trial mandate and early signs of renewed venture capital inflows into US biotech, even as near-term profitability remains weighed down by depreciation and inventory adjustments.

“We’ve secured our first global clinical trial at Phase 3, a significant milestone and a signal of an area we intend to grow further into,” Managing Director and CEO Peter Bains told businessline . The collaboration with a US biotech firm will recruit patients in both India and the US, marking Syngene’s entry into late-stage global trials.

Clinical trials

Bains added that the opportunities for the company to participate in late-stage global clinical trials are “getting stronger”, as he anticipates substantial future growth.

While underlying

See Full Page